| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Rodan GA | |
| Fleisch HA | |||
| P2860 | cites work | Human protein tyrosine phosphatase-sigma: alternative splicing and inhibition by bisphosphonates | Q28301020 |
| Bisphosphonates act on rat bone resorption through the mediation of osteoblasts | Q33898760 | ||
| The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates | Q33909532 | ||
| Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure | Q34216753 | ||
| Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice | Q35607627 | ||
| Effect of bisphosphonates on proliferation and viability of mouse bone marrow-derived macrophages | Q36458021 | ||
| Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate | Q37685549 | ||
| The effect of several diphosphonates on acid phosphohydrolases and other lysosomal enzymes | Q39983345 | ||
| Renal secretion of diphosphonates in rats | Q40338996 | ||
| Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. | Q40379763 | ||
| The when and how of Src regulation | Q40487537 | ||
| Clinical effects of bisphosphonates in involutional osteoporosis | Q40721873 | ||
| A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates | Q41122422 | ||
| Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption | Q41196903 | ||
| Importance of the paracellular pathway for the transport of a new bisphosphonate using the human CACO-2 monolayers model | Q41514890 | ||
| The influence of 1-hydroxyethane-1,1-diphosphonate and dichloromethanediphosphonate on lysine hydroxylation and cross-link formation in rat bone, cartilage and skin collagen | Q42022377 | ||
| Structure-activity relationships of various bisphosphonates | Q42259282 | ||
| A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders | Q42557625 | ||
| Acid extrusion is induced by osteoclast attachment to bone. Inhibition by alendronate and calcitonin | Q42930218 | ||
| The effects of diphosphonates on the growth and glycolysis of connective-tissue cells in culture | Q42935477 | ||
| Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix | Q44274641 | ||
| The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals | Q44967804 | ||
| Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. | Q45976835 | ||
| Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (Cl 2 MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats | Q46282954 | ||
| Effects of two novel bisphosphonates on bone cells in vitro | Q47561419 | ||
| Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group | Q48527134 | ||
| Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. | Q54153483 | ||
| Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. | Q54724724 | ||
| Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy | Q57104134 | ||
| Intermittent cyclical etidronate treatment of postmenopausal osteoporosis | Q67300571 | ||
| Retention of etidronate in human, dog, and rat | Q68178967 | ||
| The subcellular distribution of [14C]dichloromethylenebisphosphonate and [14C]1-hydroxyethylidene-1,1-bisphosphonate in cultured calvaria cells | Q70196013 | ||
| The acute-phase response after bisphosphonate administration | Q70376821 | ||
| The influence of two diphosphonates on calcium metabolism in the rat | Q70411015 | ||
| Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis | Q70583314 | ||
| Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo | Q71207806 | ||
| Influence of a diphosphonate on the cellular aspect of young bone tissue | Q71520540 | ||
| Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate | Q71773706 | ||
| The effects of risedronate on canine cancellous bone remodeling: three-dimensional kinetic reconstruction of the remodeling site | Q72248081 | ||
| Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models | Q72251064 | ||
| Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo | Q72434479 | ||
| Lipophilic 1,1-bisphosphonates are potent squalene synthase inhibitors and orally active cholesterol lowering agents in vivo | Q72571828 | ||
| Inhibitory effects of bisphosphonates on growth of amoebae of the cellular slime mold Dictyostelium discoideum | Q72758768 | ||
| Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss | Q72838186 | ||
| Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis | Q72879073 | ||
| Studies on x ray absorption and diffraction of bone tissue | Q76137662 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2692-2696 | |
| P577 | publication date | 1996-06-01 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Bisphosphonates: mechanisms of action. | |
| P478 | volume | 97 |
| Q37679606 | A closer look at the immediate trabecula response to combined parathyroid hormone and alendronate treatment. |
| Q36862150 | A comparative study of zoledronic acid and once weekly Alendronate in the management of acute Charcot arthropathy of foot in patients with diabetes mellitus |
| Q36337716 | A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis |
| Q34469883 | A systematic review of microsurgical reconstruction of the jaws using vascularized fibula flap technique in patients with bisphosphonate-related osteonecrosis |
| Q36216730 | Adjuvant pamidronate therapy prevents the development of bone metastases in breast cancer patients with four or more positive nodes |
| Q34583705 | Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis |
| Q46898891 | Adsorption on apatitic calcium phosphates for drug delivery: interaction with bisphosphonate molecules. |
| Q27024641 | Advanced glycation end products play adverse proinflammatory activities in osteoporosis |
| Q36327078 | Advances in the management of myeloma bone disease |
| Q43283348 | Alendronate binds to tooth root surfaces and inhibits progression of feline tooth resorption: a pilot proof-of-concept study |
| Q47974235 | Alendronate blocks TGF-beta1 stimulated collagen 1 degradation by human prostate PC-3 ML cells |
| Q77352882 | Alendronate blocks metalloproteinase secretion and bone collagen I release by PC-3 ML cells in SCID mice |
| Q37411072 | Alendronate enhances osteogenic differentiation of bone marrow stromal cells: a preliminary study |
| Q34793691 | Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro |
| Q38848318 | Alendronate-Eluting Biphasic Calcium Phosphate (BCP) Scaffolds Stimulate Osteogenic Differentiation |
| Q92309852 | Alendronate-Functionalized Poly(2-oxazoline)s with Tunable Affinity for Calcium Cations |
| Q43272889 | Amelioration of hypophosphatemic rickets and osteoporosis with pamidronate and growth hormone in Lowe syndrome |
| Q27027254 | American Society of Biomechanics Journal of Biomechanics Award 2013: cortical bone tissue mechanical quality and biological mechanisms possibly underlying atypical fractures |
| Q46290855 | Amorphous calcium phosphate-mediated binding of matrix metalloproteinase-9 to fibrin is inhibited by pyrophosphate and bisphosphonate |
| Q49895842 | An Essential Warning |
| Q77841872 | An ultrastructural study of the effects of bisphosphonate administration on osteoclastic bone resorption during relapse of experimentally moved rat molars |
| Q34207012 | An update on glucocorticoid-induced osteoporosis |
| Q34765502 | Anatomic site variability in rat skeletal uptake and desorption of fluorescently labeled bisphosphonate |
| Q33536291 | Anti-tumour activity of bisphosphonates in human myeloma cells. |
| Q33897197 | Antitumour effects of bisphosphonates: first evidence and possible mechanisms |
| Q34984018 | Are bisphosphonates effective in the treatment of osteoarthritis pain? A meta-analysis and systematic review |
| Q53665718 | Are macrophages in tumors good targets for novel therapeutic approaches? |
| Q30275126 | Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo |
| Q37414183 | Assessment of corticosteroid-induced osteonecrosis in children undergoing chemotherapy for acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group |
| Q38313121 | Association between histomorphometry and biochemical markers of bone turnover in a longitudinal rat model of parathyroid hormone-related peptide (PTHrP)-mediated tumor osteolysis |
| Q41477033 | Atypical fracture with long-term bisphosphonate therapy is associated with altered cortical composition and reduced fracture resistance. |
| Q46287987 | Biphosphonates in children: present and future |
| Q43181955 | Birefringence of the secretory-stage enamel organic extracellular matrix from rats submitted to successive injections of bisphosphonates |
| Q34182079 | Bisphosphonate associated osteonecrosis of the jaw: an update on pathophysiology, risk factors, and treatment |
| Q48283228 | Bisphosphonate guidelines for treatment and prevention of myeloma bone disease |
| Q36181162 | Bisphosphonate induced osteonecrosis of jaw in breast cancer patients: A systematic review |
| Q36527045 | Bisphosphonate-related osteonecrosis of the jaw in metastatic breast cancer patients: a review of 25 cases |
| Q38215499 | Bisphosphonate-related osteonecrosis of the jaw: a review of the literature |
| Q53588275 | Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. |
| Q37215597 | Bisphosphonate-related osteonecrosis of the jaws (Bronj). |
| Q34581585 | Bisphosphonates and atherosclerosis |
| Q33666457 | Bisphosphonates and osteonecrosis of the jaw: moving from the bedside to the bench. |
| Q35095548 | Bisphosphonates in Breast Cancer Patients with Bone Metastases |
| Q35547563 | Bisphosphonates in bone cement inhibit PMMA particle induced bone resorption |
| Q40835115 | Bisphosphonates in bone diseases |
| Q33898576 | Bisphosphonates in the adjuvant treatment of cancer: experimental evidence and first clinical results. International Bone and Cancer Study Group (IBCG). |
| Q74325397 | Bisphosphonates inhibit IL-6 production by human osteoblast-like cells |
| Q46291792 | Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo |
| Q37982663 | Bisphosphonates: effects on osteoblast |
| Q33807859 | Bisphosphonates: from grandparents to grandchildren |
| Q41387009 | Bisphosphonates: preclinical aspects and use in osteoporosis |
| Q45228145 | Bone densitometry in pediatric patients treated with pamidronate |
| Q42955767 | Bone marker response in chronic diffuse sclerosing osteomyelitis treated with intravenous ibandronate |
| Q36421443 | Bone metabolism and clinical study of 44 patients with bisphosphonate-related osteonecrosis of the jaws |
| Q35069358 | Bone metastases in breast cancer |
| Q45331855 | Bone mineral density changes of lumbar spine and femur in osteoporotic patient treated with bisphosphonates and beta-hydroxy-beta-methylbutyrate (HMB): Case report |
| Q84878929 | Bone targeted therapies in early breast cancer |
| Q39356298 | Bone-seeking agents for the treatment of bone disorders |
| Q27693259 | Breast cancer chemoprevention: old and new approaches |
| Q89986604 | Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial |
| Q47404990 | Calcific aortic valve stenosis: hard disease in the heart: A biomolecular approach towards diagnosis and treatment. |
| Q35156035 | Cancer treatment dosing regimens of zoledronic acid result in near-complete suppression of mandible intracortical bone remodeling in beagle dogs |
| Q37323596 | Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate. |
| Q44058144 | Characterization of the bone-resorptive effect of interleukin-11 in cultured mouse calvarial bones |
| Q60928216 | Combined effect of recombinant human bone morphogenetic protein-2 and low level laser irradiation on bisphosphonate-treated osteoblasts |
| Q88209001 | Combined pharmacotherapy for osteonecrosis of the femoral head after severe acute respiratory syndrome and interstitial pneumonia: two and a half to fourteen year follow-up |
| Q37018947 | Comparative effects of antiresorptive agents on bone mineral density and bone turnover in postmenopausal women |
| Q46612827 | Comparison of alendronate and raloxifene for the management of primary hyperparathyroidism |
| Q51797784 | Comparison of the efficacy of denosumab and bisphosphonates for treating secondary osteoporosis in patients with rheumatoid arthritis. |
| Q44010369 | Complete healing of severe osteoradionecrosis with treatment combining pentoxifylline, tocopherol and clodronate |
| Q53477677 | Computerized tomographic findings in bisphosphonate-associated osteonecrosis of the jaw in patients with cancer. |
| Q37111174 | Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo |
| Q26864483 | Consequences of irradiation on bone and marrow phenotypes, and its relation to disruption of hematopoietic precursors |
| Q37720485 | Copper accumulation in the sequestrum of medication-related osteonecrosis of the jaw. |
| Q37183557 | Current trends in multiple myeloma management |
| Q37731222 | Design and Biological Evaluation of Delivery Systems Containing Bisphosphonates |
| Q44395937 | Determination of clodronate content in liposomal formulation by capillary zone electrophoresis |
| Q38667546 | Development of Bone Targeting Drugs. |
| Q78747200 | Development of matrix metalloproteinase inhibitors in cancer therapy |
| Q36065420 | Discovery, clinical development, and therapeutic uses of bisphosphonates |
| Q48437472 | Disodium pamidronate for treating severe hypercalcemia in a hemodialysis patient |
| Q36800774 | Dissociation between bone resorption and bone formation in osteopenic transgenic mice |
| Q36491529 | Does estrogen play a role in response to adjuvant bone-targeted therapies? |
| Q41502574 | Donor pulmonary intravascular nonclassical monocytes recruit recipient neutrophils and mediate primary lung allograft dysfunction |
| Q36514754 | Dual Effects of Bisphosphonates on Ectopic Skin and Vascular Soft Tissue Mineralization versus Bone Microarchitecture in a Mouse Model of Generalized Arterial Calcification of Infancy |
| Q46063122 | Eel calcitonin (elcatonin) suppressed callus remodeling but did not interfere with fracture healing in the femoral fracture model of cynomolgus monkeys |
| Q43686386 | Effect of 17beta-estradiol or alendronate on the bone densitometry, bone histomorphometry and bone metabolism of ovariectomized rats |
| Q34129152 | Effect of Bisphosphonates on the Progression of Degenerative Aortic Stenosis |
| Q73235421 | Effect of alendronate treatment on the osteoclastogenic potential of bone marrow cells in mice |
| Q36229094 | Effect of low-level laser therapy on bisphosphonate-treated osteoblasts |
| Q53096539 | Effects of Pamidronate on Dental Enamel Formation Assessed by Light Microscopy, Energy-Dispersive X-Ray Analysis, Scanning Electron Microscopy, and Microhardness Testing. |
| Q42905765 | Effects of alendronate on bone healing after tooth extraction in rats |
| Q46042275 | Effects of alendronate on the proliferation and osteogenic differentiation of MG-63 cells |
| Q40897306 | Effects of bisphosphonate on experimental jaw metastasis model in nude mice |
| Q50454766 | Effects of bisphosphonates on osteogenesis and osteoclastogenesis signaling during the endochondral ossification of growing rats. |
| Q37392009 | Effects of clodronate and alendronate on osteoclast and osteoblast co-cultures on silk-hydroxyapatite films |
| Q42834095 | Effects of clodronate on early alveolar bone remodeling and root resorption related to orthodontic forces: A histomorphometric analysis |
| Q37631688 | Effects of dried plum supplementation on bone metabolism in adult C57BL/6 male mice |
| Q43213519 | Effects of the bisphosphonate risedronate on osteopenia in OASIS-deficient mice |
| Q46710355 | Efficacy of intravenous alendronate for the treatment of glucocorticoid-induced osteoporosis in children with autoimmune diseases |
| Q83189256 | Efficacy of low doses of pamidronate in osteopenic patients administered in the early post-renal transplant |
| Q35637157 | Enhanced affinity bifunctional bisphosphonates for targeted delivery of therapeutic agents to bone |
| Q89805481 | Ethyl Acetate Fraction of Aqueous Extract of Lentinula edodes Inhibits Osteoclastogenesis by Suppressing NFATc1 Expression |
| Q39030985 | Evidence for Use of Teriparatide in Spinal Fusion Surgery in Osteoporotic Patients |
| Q74579830 | Expanding role of bisphosphonate therapy in children |
| Q51159871 | Exploiting Bisphosphonate-Bioactive-Glass Interactions for the Development of Self-Healing and Bioactive Composite Hydrogels. |
| Q36502345 | Fragility fractures of the pelvis |
| Q37179393 | Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates |
| Q38114472 | Healing of the bone with anti-fracture drugs |
| Q38017051 | Hemimandibulectomy after bisphosphonate treatment for complex regional pain syndrome: a case report and review on the prevention and treatment of bisphosphonate-related osteonecrosis of the jaw. |
| Q89885670 | Histologic evaluation of femoral nerve demyelinating and axonal neuropathy in Wistar rats due to alendronate intake: a randomised study |
| Q51166220 | Histomorphologic characteristics of bisphosphonate-related osteonecrosis of the jaw. |
| Q73648408 | How does alendronate inhibit protein-tyrosine phosphatases? |
| Q92995357 | Hypercalcemia is common during Pneumocystis pneumonia in kidney transplant recipients |
| Q28079418 | Hypercalcemia of Malignancy |
| Q52091416 | Hyperphosphatemia in a patient with spinal cord injury who received etidronate for the treatment of heterotopic ossification. |
| Q44317962 | Hypocalcemia following pamidronate administration for bone metastases of solid tumor: three clinical case reports |
| Q39801202 | Identification of secondary targets of N-containing bisphosphonates in mammalian cells via parallel competition analysis of the barcoded yeast deletion collection. |
| Q28582189 | Immunocytochemical study of amelogenin deposition during the early odontogenesis of molars in alendronate-treated newborn rats |
| Q46433634 | Implications of high-dosage bisphosphonate treatment on bone tissue in the jaw and knee joint |
| Q44140894 | Incadronate disodium inhibits advanced glycation end products-induced angiogenesis in vitro |
| Q47325841 | Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab. |
| Q58972138 | Increments in Bone Mineral Density of the Lumbar Spine and Hip and Suppression of Bone Turnover Are Maintained after Discontinuation of Alendronate in Postmenopausal Women |
| Q47611760 | Indirect osteoblast differentiation by liposomal clodronate |
| Q39353783 | Inherited Arterial Calcification Syndromes: Etiologies and Treatment Concepts |
| Q51061548 | Inhibition of bone healing by pamidronate in calvarial bony defects. |
| Q43605201 | Inhibition of cholesteatomatous bone resorption with pamidronate disodium |
| Q57970668 | Inhibition of growth of Dictyostelium discoideum amoebae by bisphosphonate drugs is dependent on cellular uptake |
| Q42172781 | Inhibition of inflammatory actions of aminobisphosphonates by dichloromethylene bisphosphonate, a non-aminobisphosphonate |
| Q34384846 | Inositol hexakisphosphate inhibits osteoclastogenesis on RAW 264.7 cells and human primary osteoclasts |
| Q40617031 | Involvement of interleukin-1 in the inflammatory actions of aminobisphosphonates in mice |
| Q40857866 | Is all bone the same? Distinctive distributions and properties of non-collagenous matrix proteins in lamellar vs. woven bone imply the existence of different underlying osteogenic mechanisms |
| Q38248821 | Isoprenoid biosynthesis in Plasmodium falciparum |
| Q53477422 | Jaw osteonecrosis in patients treated with bisphosphonates: MDCT evaluation. |
| Q34238507 | Lack of Correlation Between Duration of Osteonecrosis of the Jaw and Sequestra Tissue Morphology: What It Tells Us About the Condition and What It Means for Future Studies |
| Q38757607 | Long-Term Oral Bisphosphonate Therapy and Fractures in Older Women: The Women's Health Initiative |
| Q28165627 | Long-term analgesic effect of clodronate in rodents |
| Q39129914 | Macrophages and skeletal health |
| Q90329508 | Magnesium and Anti-phosphate Treatment with Bisphosphonates for Generalised Arterial Calcification of Infancy: A Case Report |
| Q51183940 | Material properties of bone in the femoral head treated with ibandronate and BMP-2 following ischemic osteonecrosis. |
| Q44878611 | Mature bone radionecrosis: from recent physiopathological knowledge to an innovative therapeutic action |
| Q33895238 | Metabolic effects of vanadyl sulfate in humans with non-insulin-dependent diabetes mellitus: in vivo and in vitro studies |
| Q58613918 | Mineral and Bone Disease in Kidney Transplant Recipients |
| Q55077666 | Minodronate for the treatment of osteoporosis. |
| Q33914500 | Morphological assessment of basic multicellular unit resorption parameters in dogs shows additional mechanisms of bisphosphonate effects on bone |
| Q77312697 | Morphology of bone metastasis |
| Q33606107 | Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer |
| Q28082461 | Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy |
| Q38269370 | Myeloid-derived suppressor cells: their role in the pathophysiology of hematologic malignancies and potential as therapeutic targets |
| Q35145878 | New methodology for evaluating osteoclastic activity induced by orthodontic load |
| Q24657667 | Once-yearly zoledronic acid in hip fracture prevention |
| Q36218415 | Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (Oryzomys palustris) with periodontitis |
| Q57147876 | Optimizing Sequential and Combined Anabolic and Antiresorptive Osteoporosis Therapy |
| Q33827663 | Osteoblastic protein tyrosine phosphatases inhibition and connexin 43 phosphorylation by alendronate |
| Q36891833 | Osteoblastic responses to TGF-beta during bone remodeling |
| Q35240281 | Osteonecrosis of jaws related to intravenous bisphosphonates: the experience of a Jordanian teaching hospital |
| Q53521337 | Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients. |
| Q34178759 | Osteoporosis and gastrointestinal disease |
| Q78166986 | Osteoporosis for the allergist |
| Q93182236 | PXE, a Mysterious Inborn Error Clarified |
| Q41530938 | Paget's disease of bone: clinical, pathogenetic and therapeutic aspects |
| Q41690947 | Paget's disease of bone: indications for treatment and goals of therapy |
| Q46816492 | Pamidronate treatment of hypercalcemia caused by vitamin D toxicity |
| Q37180257 | Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation |
| Q41460446 | Pathogenesis and management of bone lesions in multiple myeloma |
| Q35660101 | Pathogenesis of aortic stenosis: not just a matter of wear and tear |
| Q37170651 | Pathologic fractures in bisphosphonate-related osteonecrosis of the jaw-review of the literature and review of our own cases |
| Q89860655 | Pathological Crosstalk between Metastatic Breast Cancer Cells and the Bone Microenvironment |
| Q44941835 | Peri-implant bone remodeling after total hip replacement combined with systemic alendronate treatment: a finite element analysis. |
| Q85888167 | Periosteal microcirculatory reactions in a zoledronate-induced osteonecrosis model of the jaw in rats |
| Q92557680 | Pharmacoepidemiology and clinical characteristics of medication-related osteonecrosis of the jaw |
| Q37492019 | Phosphate: an old bone molecule but new cardiovascular risk factor |
| Q73519376 | Poly(2-hydroxy ethyl methacrylate)-alkaline phosphatase: a composite biomaterial allowing in vitro studies of bisphosphonates on the mineralization process |
| Q35480967 | Prevalence, pathophysiology, screening and management of osteoporosis in gastric cancer patients |
| Q33857775 | Prevention and treatment of systemic glucocorticoid side effects |
| Q33902085 | Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin |
| Q46884243 | Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer |
| Q37858249 | Preventive therapy for breast cancer: a consensus statement |
| Q34275146 | Prolonged, symptomatic hypocalcemia with pamidronate administration and subclinical hypoparathyroidism |
| Q84189608 | Protective effect of myo-inositol hexaphosphate (phytate) on bone mass loss in postmenopausal women |
| Q35601653 | Proven efficacy of zoledronic acid in the treatment of bone metastases in patients with breast cancer and other malignancies |
| Q35112631 | Radiographic features of bisphosphonate therapy in pediatric patients |
| Q36203263 | Rational use of oral bisphosphonates for the treatment of osteoporosis |
| Q37197298 | Recovery of trabecular and cortical bone turnover after discontinuation of risedronate and alendronate therapy in ovariectomized rats |
| Q36895332 | Regulation of osteoclast polarization |
| Q78170983 | Relationship between bisphosphonate concentration and osteoclast activity and viability |
| Q38829698 | Resection and microvascular reconstruction of bisphosphonate-related osteonecrosis of the jaw: The role of microvascular reconstruction |
| Q73549429 | Risk of complications from bone metastases in breast cancer. implications for management |
| Q60489259 | Roles of the RANKL–RANK axis in antitumour immunity — implications for therapy |
| Q30675849 | Selective inhibition of beta-1,4- and alpha-1,3-galactosyltransferases: donor sugar-nucleotide based approach |
| Q50659162 | Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy. |
| Q34488062 | Severe resistant hypocalcemia in multiple myeloma after zoledronic acid administration: a case report |
| Q33893365 | Steroid-induced osteoporosis in systemic lupus erythematosus |
| Q44753314 | Successful management of severe facial pain in patients with diffuse sclerosing osteomyelitis (DSO) of the mandible using disodium clodronate |
| Q44048554 | Synergistic growth inhibition of YM529 with biologic response modifiers (BRMs) in myeloma cells |
| Q37289359 | Systemic and local zoledronic acid treatment with hydroxyapatite bone graft: A histological and histomorphometric experimental study |
| Q47765346 | Targeting Myeloid-Derived Suppressor Cells in Cancer |
| Q33760068 | Targeting TGFβ signaling in subchondral bone and articular cartilage homeostasis |
| Q58547311 | Targeting macrophages: therapeutic approaches in cancer |
| Q57168746 | The Biological Enhancement of Spinal Fusion for Spinal Degenerative Disease |
| Q27010303 | The Effect of Teriparatide on Fracture Healing of Osteoporotic Patients: A Meta-Analysis of Randomized Controlled Trials |
| Q35650046 | The Local Effect of Alendronate with Intra-alveolar Collagen Sponges on Post Extraction Alveolar ridge Resorption: A Clinical Trial |
| Q44136623 | The absolute bioavailability of clodronate from two different oral doses |
| Q33757655 | The biology and management of bone metastases |
| Q33467586 | The combination therapy with alfacalcidol and risedronate improves the mechanical property in lumbar spine by affecting the material properties in an ovariectomized rat model of osteoporosis |
| Q47096700 | The effect of low-dose intravenous bisphosphonate treatment on osteoporosis in children with quadriplegic cerebral palsy. |
| Q36215878 | The effect of sequential therapy for postmenopausal women with osteoporosis: A PRISMA-compliant meta-analysis of randomized controlled trials. |
| Q47603207 | The effect of systemically administrated zoledronic acid on the osseointegration of dental implants |
| Q36189282 | The effects of bisphosphonates on ectopic soft tissue mineralization caused by mutations in the ABCC6 gene |
| Q37832692 | The effects of bisphosphonates on jaw bone remodeling, tissue properties, and extraction healing. |
| Q46758238 | The effects of bone therapy on tibial bone loss in young women with anorexia nervosa |
| Q51617646 | The effects of bone turnover rate on subchondral trabecular bone structure and cartilage damage in the osteoarthritis rat model. |
| Q43427952 | The effects of disodium pamidronate on human polymorphonuclear leukocytes and platelets: an in vitro study. |
| Q35842418 | The effects of zoledronate on the survival and function of human osteoblast-like cells |
| Q36671015 | The effects of zoledronic acid in the bone and vasculature support of hematopoietic stem cell niches |
| Q35936280 | The epidemiology of distal radius fractures |
| Q45270306 | The influence of alendronate on bone formation after autogenous free bone grafting in rats |
| Q40385248 | The inhibitory effect of alendronate, a nitrogen-containing bisphosphonate on the PI3K-Akt-NFkappaB pathway in osteosarcoma cells |
| Q81376464 | The protective effects of incadronate on inflammation and joint destruction in established rat adjuvant arthritis |
| Q33700394 | The resistance of cortical bone tissue to failure under cyclic loading is reduced with alendronate |
| Q36450794 | The role of bisphosphonates in the management of prostate cancer |
| Q37305028 | Theoretical analysis of alendronate and risedronate effects on canine vertebral remodeling and microdamage |
| Q33906777 | Treatment of bisphosphonate-induced osteonecrosis of the jaws with Nd:YAG laser biostimulation |
| Q46607026 | Treatment of experimental renal osteodystrophy with pamidronate |
| Q35453039 | Treatment of immobilization-related hypercalcaemia with denosumab |
| Q44048434 | Treatment of osteoporosis and osteopenia in long-term renal transplant patients with alendronate |
| Q74787561 | Treatment of osteoporosis with bisphosphonates |
| Q35547309 | Tumour macrophages as potential targets of bisphosphonates. |
| Q37812617 | Use of medications and risk of revision after primary total hip arthroplasty |
| Q41471544 | Utility of bisphosphonates in treating bone metastases |
| Q51744485 | Zoledronic Acid in the Treatment of Bone Metastases from Differentiated Thyroid Carcinoma |
| Q54080943 | Zoledronic acid and clodronate in the treatment of malignant bone metastases with hypercalcaemia; efficacy and safety comparative study. |
| Q36846801 | Zoledronic acid in metastatic osteosarcoma: encouraging progression free survival in four consecutive patients |
| Q35108947 | μCT-based, in vivo dynamic bone histomorphometry allows 3D evaluation of the early responses of bone resorption and formation to PTH and alendronate combination therapy |
Search more.